CCR6 and neoplasm: In line with this observation, splenic CCR6+ ILC3s cells can, after activation by IL-12, suppress tumor growth and increase immune cell recruitment (specifically CD8 T cells, NK, and NKT cells as well as activated myeloid cells) in the B16 melanoma mouse model.